Deutsche Bank has initiated coverage on Spyre Therapeutics Inc (SYRE) with a Buy rating, marking the firm's first assessment of the biotechnology company. Spyre Therapeutics, headquartered in Waltham, Massachusetts, focuses on developing next-generation human enzyme therapeutics aimed at treating rare and high-burden diseases.
As of September 25, 2025, Spyre's stock is priced at $24.55, reflecting its current market capitalization of $1.8 billion. The company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23, with its advanced candidate, SPY001, designed for the treatment of inflammatory bowel disease (IBD).
Analyst ratings, such as the one from Deutsche Bank, provide insights based on research and financial models, although they are subject to change as new information becomes available. This update provides insight into the growing interest in Spyre's innovative therapeutic approaches, particularly as the company prepares for upcoming earnings reports, with EPS estimates of $-0.65 and $-0.63 for the quarters ending August 3, 2026, and May 6, 2026, respectively.
With a consensus rating of Buy among analysts, which includes 10 Strong Buy, 7 Buy, and 2 Hold ratings, Spyre Therapeutics is positioned as a notable player in the biotechnology sector. However, investment decisions should consider a range of factors, including company fundamentals and market conditions.